# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Duffy Fischer maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $29 to $23.
Multi-Million-Dollar Investment Supports Hybrid And Electric Vehicle Advancements
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $25 to $18.
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Buy and lowers the price target from $30 to $28.
Barclays analyst Michael Leithead maintains Chemours (NYSE:CC) with a Equal-Weight and lowers the price target from $30 to $22.